 | BeyondSpring, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 5:08 PM |
 | BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
finance.yahoo.com - March 5 at 11:24 AM |
 | Beyondspring's (BYSI) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 4 at 10:50 AM |
 | BeyondSpring's Plinabulin shows positive action in mid-stage breast cancer study
seekingalpha.com - February 26 at 11:32 AM |
| New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
finance.yahoo.com - February 26 at 11:32 AM |
| BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin
finance.yahoo.com - December 27 at 10:41 AM |
| USPTO issues composition of matter patent with BeyondSpring’s plinabulin with protection to 2036
seekingalpha.com - December 21 at 10:21 AM |
| United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036
finance.yahoo.com - December 21 at 10:21 AM |
| BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%
seekingalpha.com - December 6 at 3:59 PM |
| BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
finance.yahoo.com - December 6 at 10:07 AM |
| Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF
finance.yahoo.com - December 4 at 4:00 PM |
| Can The Uptrend Continue for BeyondSpring (BYSI)?
finance.yahoo.com - November 30 at 11:10 AM |
 | BeyondSpring (BYSI) Says Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
www.streetinsider.com - November 27 at 3:49 PM |
| Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
finance.yahoo.com - November 27 at 10:58 AM |
| BeyondSpring up 17% on positive plinabulin data
seekingalpha.com - November 9 at 3:52 PM |
| Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®
finance.yahoo.com - November 8 at 10:18 AM |
| BeyondSpring's Plinabulin shows positive effect in preventing chemo-induced neutropenia
seekingalpha.com - October 23 at 3:46 PM |
| BeyondSpring Inc. (BYSI) CEO Lan Huang on Clinical Update Conference Call Transcript
seekingalpha.com - October 23 at 3:46 PM |
| BeyondSpring (BYSI) Announces Efficacy and Safety Data from Phase 2 Study 106 with Plinabulin for CIN Prevention
www.streetinsider.com - October 23 at 10:10 AM |
| BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention
finance.yahoo.com - October 23 at 10:10 AM |
| BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment
finance.yahoo.com - October 23 at 10:10 AM |
| Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Results
finance.yahoo.com - October 23 at 10:10 AM |
| BeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSF
finance.yahoo.com - October 16 at 10:03 AM |
| Who Really Owns BeyondSpring Inc (NASDAQ:BYSI)?
finance.yahoo.com - October 5 at 3:45 PM |
| Study Opens of BeyondSpring’s Lead Asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung Cancer
finance.yahoo.com - October 4 at 9:44 AM |
| BeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific Conferences
finance.yahoo.com - October 3 at 9:57 AM |
| BeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for Neutropenia
finance.yahoo.com - September 25 at 10:04 AM |
| BeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for Plinabulin
finance.yahoo.com - September 19 at 10:15 AM |
| BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
finance.yahoo.com - September 6 at 10:40 AM |
| BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung Cancer
finance.yahoo.com - August 15 at 10:21 AM |
| BeyondSpring Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - August 7 at 10:33 AM |
| BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization
finance.yahoo.com - August 1 at 12:14 PM |
| BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists
finance.yahoo.com - June 25 at 12:17 PM |
 | BeyondSpring, Inc. (BYSI) Q1 2018 Earnings Conference Call Transcript
www.msn.com - June 22 at 12:12 PM |
| BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results
finance.yahoo.com - June 21 at 12:00 PM |
| BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018
finance.yahoo.com - June 18 at 12:48 PM |
| BeyondSpring to Present at Upcoming Conferences
finance.yahoo.com - May 31 at 10:42 AM |
| BeyondSpring commences direct stock offering at $27.06
seekingalpha.com - May 30 at 3:46 PM |
| BeyondSpring Announces $20 Million Registered Direct Offering
finance.yahoo.com - May 30 at 10:27 AM |
| BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
finance.yahoo.com - May 17 at 10:44 AM |
| BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - May 15 at 11:08 AM |
 | BRIEF-BeyondSpring Says May Offer And Sell Up To 5 Mln Of Co's Ordinary Share From Time to Time
www.reuters.com - April 26 at 10:09 AM |
| BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting
finance.yahoo.com - April 26 at 10:09 AM |
| BeyondSpring CEO Reveals Novel Tumor Therapy
finance.yahoo.com - April 25 at 3:49 PM |
| BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
finance.yahoo.com - April 17 at 10:47 AM |
| Why BeyondSpring (BYSI) Could Be a Potential Winner
finance.yahoo.com - April 12 at 11:27 AM |
| BeyondSpring's (BYSI) CEO Lan Huang on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - April 5 at 8:54 AM |
| BeyondSpring Files Its 2017 Annual Report on Form 20-F
finance.yahoo.com - April 4 at 5:11 PM |
| BRIEF-Beyondspring Qtrly Loss Per Share $0.68
www.reuters.com - April 3 at 10:49 AM |
| BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - April 3 at 10:49 AM |
